We aimed to investigate whether the reduced incretin effect observed in patients with type 2 diabetes is a primary event in the pathogenesis of type 2 diabetes or a consequence of the diabetic state.

The lower sales guidance was a result of sluggish growth in the market for incretin, which increases insulin levels. “Sales of Mounjaro and Zepbound posted robust sales growth in Q4, and we ...

Now, with a pipeline chock-full of numerous incretin therapies, the Big Pharma's new strategy will be to test some of those drugs across neurology and immunology indications. "A new focus area ...

Management expects significant contributions from U.S. incretin class growth and international Mounjaro launches. Earnings per share (EPS) for 2025 are projected at $22.50 to $24.00. Management ...

The lower sales guidance was a result of sluggish growth in the market for incretin, which increases insulin levels. "Sales of Mounjaro and Zepbound posted robust sales growth in Q4, and we expect ...